Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study

Cutis

Volumn 91, Issue 4, 2013, Pages 203-210

  Jarratt, Michael ^a   Jones, Terry ^b   Kempers, Steven ^c   Rich, Phoebe ^d   Morton, Katy ^e   Nakamura, Norifumi ^e   Tavakkol, Amir ^e  

^a DermResearch Inc   (United States)

^b J and S Studies Inc   (United States)

^c Minnesota Clinical Study Center   (United States)

^d Oregon Dermatology and Research Center   (United States)

^e Topica Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2,4 DICHLOROPHENYL) 1,3 DITHIOLAN 2 YLIDENE 1 IMIDAZOLYLACETONITRILE; 4-(2,4-DICHLOROPHENYL)-1,3-DITHIOLAN-2-YLIDENE-1-IMIDAZOLYLACETONITRILE; ANTIFUNGAL AGENT; IMIDAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME; TINEA PEDIS; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TINEA PEDIS; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879954054     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician. 2002;65:2095-2102.
2. Al Hasan M, Fitzgerald SM, Saoudian M, et al. Dermatology for the practicing allergist: tinea pedis and its complications. Clin Mol Allergy. 2004;2:5.
3. Panackal AA, Halpern EF, Watson AJ. Cutaneous fungal infections in the United States: analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995-2004. Int J Dermatol. 2009;48:704-712.
4. Elmets CA. Management of common superficial fungal infections in patients with AIDS. J Am Acad Dermatol. 1994;31(3, pt 2):S60-S63.
5. Bristow I. Non-ulcerative skin pathologies of the diabetic foot. Diabetes Metab Res Rev. 2008;24(suppl 1):S84-S89.
6. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50:748-752.
7. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(2, pt 1):282-286.
8. Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother. 2004;10:216-219.
9. Koga H, Tsuji Y, Inoue K, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother. 2006;12:163-165.
10. Koga H, Nanjoh Y, Makimura K, et al. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol. 2009;47:640-647.
11. Ghannoum MA, Long L, Kim HG, et al. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Med Mycol. 2010;48:491-497.
12. Watanabe S, Takahashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis-comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses. 2007;50:35-40.
13. Gupta AK, Einarson TR, Summerbell RC, et al. An overview of topical antifungal therapy in dermatomycoses. a North American perspective. Drugs. 1998;55:645-674.